MedTech Dive March 3, 2025
Boston Scientific looks to catch up with Medtronic and Recor Medical in the much-hyped renal denervation space with its Sonivie acquisition.
Dive Brief:
- Boston Scientific has agreed to buy renal denervation firm Sonivie for up to $540 million, adding yet another acquisition to the company’s growing M&A list.
- Boston Scientific, which owns about a 10% equity stake in Sonivie, will make an upfront payment of approximately $360 million for the remaining 90% stake and offer up to $180 million in a regulatory milestone payment, according to the Monday announcement. The deal is expected to close in the first half of 2025.
- Over the past year, Boston Scientific has been one of the medtech industry’s biggest spenders. The company’s deal-making...
Today's Sponsors
Today's Sponsor